Qiagen

Founders Metin Colpan

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 10
Average round size
info
The average size of a deal this fund participated in
$11M
Portfolio companies 9
Rounds per year 0.28
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.10
Exits 6
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Diagnostics
  • Genetics
  • Health Care
  • Life Science
Summary

Qiagen appeared to be the Corporate Investor, which was created in 1986. The fund was located in Europe if to be more exact in The Netherlands. The main office of represented Corporate Investor is situated in the Venlo.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Qiagen, startups are often financed by S-Venture Capital Dortmund, NGN Capital, Forbion Capital Partners. The meaningful sponsors for the fund in investment in the same round are NGN Capital, Forbion Capital Partners, Arcus Ventures. In the next rounds fund is usually obtained by Techno Venture Management, NGN Capital, Forbion Capital Partners.

The fund is constantly included in less than 2 investment rounds annually. The increased amount of exits for fund were in 2019. The high activity for fund was in 2014. Opposing the other organizations, this Qiagen works on 28 percentage points more the average amount of lead investments. Speaking about the real fund results, this Corporate Investor is 23 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Exosome Diagnostics, Ingenium Pharmaceuticals AG, Xagenic. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups. Among the most successful fund investment fields, there are Health Care, Manufacturing.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Qiagen:
Typical Co-investors
Qiagen is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Qiagen:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alrov Group Israel, Tel Aviv District, Tel Aviv-Yafo
Beagle Ventures Chile, Region Metropolitana, Santiago
BT England, London, United Kingdom
Chuangrong Financial China, Guangdong, Shenzhen
Digital Assets Group Stockholm, Stockholm County, Sweden
Gepafin Italy, Perugia, Umbria
Independent Growth Finance (IGF) Kent, Tonbridge, United Kingdom
MBG Schleswig-Holstein Germany, Kiel, Schleswig-Holstein
Unpopular Ventures California, San Francisco, United States
Yinshengtai Capital -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Glyphic Biotechnologies

Biotechnology
Life Science
$40K19 Jan 2022 San Francisco, California, United States

Actome

Biopharma
Biotechnology
Life Science
01 Jul 2021 Freiburg im Breisgau, Baden-Württemberg, Germany

ArcherDX

Biopharma
Biotechnology
Genetics
Life Science
$35M20 Mar 2018 Boulder, Colorado, United States

Exosome Diagnostics

Biotechnology
Genetics
Health Care
Health Diagnostics
$16M07 Jan 2016 New York, New York, United States

Protagen

Biotechnology
Health Diagnostics
Medical Device
$11M17 Dec 2014 Dortmund, North Rhine-Westphalia, Germany

Exosome Diagnostics

Biotechnology
Genetics
Health Care
Health Diagnostics
$27M11 Mar 2014 New York, New York, United States

Drug Response Dx

Biotechnology
08 Jan 2013 Germany, Brandenburg, Germany

Xagenic

Biotechnology
Health Diagnostics
Medical Device
$10M30 Jan 2012 Ontario

Coley Pharmaceutical Group

Biotechnology
Health Care
Medical
$12M03 Aug 1999 Wellesley, Massachusetts, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Qiagen?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: